FOSCARNET PRESCRIBING INFORMATION PDF

are concise point-of-care prescribing, dosing and administering information to Prior to the initial foscarnet infusion, establish diuresis by administering Prehydrate with mL NS or D5W before first infusion to decrease risk for nephrotoxicity. See prescribing information for dose adjustments for CrCl < Group: antiviral. Solution for injection, 24 mg/ml ml, ml [non-EDL]. General information. Foscarnet is a non-nucleoside pyrophosphate analogue given.

Author: Fegrel Kakora
Country: Kosovo
Language: English (Spanish)
Genre: Politics
Published (Last): 22 June 2007
Pages: 85
PDF File Size: 5.12 Mb
ePub File Size: 10.87 Mb
ISBN: 767-5-54110-344-2
Downloads: 30916
Price: Free* [*Free Regsitration Required]
Uploader: Dalabar

Nilvadipine The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Nilvadipine.

WHO Model Prescribing Information: Drugs Used in HIV-Related Infections: Drugs: Foscarnet

Acetaminophen Foscarnet may decrease the excretion rate of Acetaminophen which could result in a higher serum level. Potassium perchlorate Foscarnet may decrease the excretion rate of Potassium perchlorate which could result in a higher serum level. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as iloperidone. Dilute under aseptic conditions.

Artemether The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Artemether. Safety and efficacy data are limited for patients with renal impairment as assessed by baseline serum creatinine SCr levels over 2. Marketing authorisation number s 9. Loratadine The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Loratadine.

The renal adverse effects are usually, but not always, reversible upon discontinuation or dose adjustment.

Isepamicin The risk or severity of nephrotoxicity can be increased when Isepamicin is combined with Foscarnet. Hyoscyamine The risk or severity of QTc prolongation can be increased when Prescribinng is combined with Foscarnet. Creatinine renal clearance decreased, electrocardiogram abnormal, gamma-glutamyltransferase increased, alanine aminotransferase increased, aspartate aminotransferase increased, lipase increased. Feprazone The risk or severity of nephrotoxicity can be increased when Feprazone is combined with Foscarnet.

  CQ0765RT PDF

Cinnarizine The risk or severity of QTc prolongation can be increased when Foscarnet is combined informatiin Cinnarizine. Major When possible, avoid concurrent use of foscarnet with other drugs known to prolong the QT interval, such as romidepsin.

Foscavir 24 mg/ml Solution for Infusion

Although there fowcarnet no studies examining the effects of ranolazine in patients receiving other QT prolonging drugs, coadministration of such drugs may result in additive QT prolongation. Cyanocobalamin Foscarnet may decrease the excretion rate of Cyanocobalamin which could result in a higher serum level. Cyclosporine Foscarnet may increase the nephrotoxic activities of Cyclosporine.

Pentostatin Foscarnet may decrease the excretion rate of Pentostatin which could focarnet in a higher serum level. Ancestim Foscarnet may decrease the excretion rate of Ancestim which could result in a higher serum level. Fenoldopam Foscarnet may decrease the excretion rate of Fenoldopam which could result in a higher serum level.

PDR Search

Major Avoid the concomitant use of midostaurin and foscarnet; both drugs have been reported to increase the QT interval. Lisinopril Foscarnet may decrease the excretion rate of Lisinopril which could result in lrescribing higher serum level.

Chlorprothixene The risk or severity of QTc prolongation can be increased when Foscarnet is combined with Chlorprothixene. It prescrbiing unknown if this agent crosses the placenta or is distributed into breast milk. Cefazedone The risk or severity of nephrotoxicity can be increased when Cefazedone is combined with Foscarnet. Aceclofenac The risk or severity of nephrotoxicity can be increased when Aceclofenac is combined with Foscarnet.

Pamidronate The risk or severity of nephrotoxicity can be increased when Pamidronate is combined with Foscarnet. Garenoxacin Informatiion risk or severity of QTc prolongation can be increased when Foscarnet is combined with Garenoxacin.

Cefalotin The risk or severity of nephrotoxicity can be increased when Cefalotin is combined with Foscarnet. Cimetidine Foscarnet may decrease the excretion rate of Cimetidine which could result in a higher serum level. Pemetrexed Foscarnet may decrease the excretion rate of Pemetrexed which could result in a higher serum level. Individually dispensed doses of foscarnet should be aseptically transferred and diluted with equal parts of 0. Estazolam Foscarnet may decrease the excretion rate of Estazolam which could result in a higher serum level.

  PSICOLOGIA ORGANIZACIONAL FURNHAM PDF

Patent US, issued February, It has been shown voscarnet hydration, to induce diuresis, significantly reduces kidney changes during foscarnet treatment.

In case of overdose, call the poison control helpline at Corifollitropin alfa Foscarnet may decrease the excretion rate of Corifollitropin alfa which could result in a higher serum level. Prasugrel Foscarnet may decrease the excretion rate of Prasugrel which could result in a higher serum level. Major Consider the risks and benefits of treatment with talimogene laherparepvec before administering acyclovir or other antivirals to prevent or manage herpetic infection.

Dronedarone The risk or infkrmation of QTc prolongation can be increased when Foscarnet is combined with Dronedarone. QTc prolongation has also been reported with the use of degarelix. Therefore, patients must be carefully monitored for such changes and their potential sequelae. The safety and efficacy of foscarnet in children have not been established. Invormation Foscarnet may decrease the excretion rate of Nefazodone which could result in a higher serum level.

Infection recurred in most patients a median of 14 days after foscarnet therapy was discontinued. QT prolongation and TdP have also been reported in patients treated with fluoxetine. Isoxicam The risk or severity of nephrotoxicity can be increased when Isoxicam is combined with Foscarnet.